search
Back to results

Effect of Nutritional Intervention and Olive Oil in Severe Obesity

Primary Purpose

Severe Obesity

Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Nutritional intervention
Nutritional intervention plus olive oil
Olive oil
Sponsored by
Universidade Federal de Goias
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Severe Obesity focused on measuring nutritional management, olive oil, weight loss, body composition, nutrigenomics, polymorphisms, cardiovascular risk, sarcopenia, inflammation, food intake, sedentary lifestyle, patient adherence, bone density

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Body mass index ≥ 35 kg/m2
  • Residence in Goiânia or metropolitan area
  • Patients referred by Secretaria Municipal de Saúde to Severe Obese Nutrition Clinic

Exclusion Criteria:

  • To have already performed bariatric surgery
  • Pregnancy
  • Reduction greater than 8% of body weight in the past 3 months
  • To have been treated at Severe Obesity Nutrition Clinic or have received nutritional counseling in another place in the last 2 years
  • Anti-obesity drugs use
  • Regular utilization of anti-inflammatory drugs or corticosteroids
  • HIV/AIDS, heart failure, kidney failure, hepatic insufficiency, chronic obstructive pulmonary disease and cancer

Sites / Locations

  • Unidade de Pesquisa Clínica do Hospital das Clínicas/UFG

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Nutritional intervention

Nutritional intervention plus olive oil

Olive oil

Arm Description

Patients under only nutritional intervention for weight loss

Patients under conventional treatment (nutritional intervention) plus extra virgin olive oil supplementation

Patient under habitual food consumption plus extra virgin olive oil supplementation

Outcomes

Primary Outcome Measures

Anthropometric measurements change
Measurements of weight, arm circumference and Body Mass Index (BMI) will be evaluated to assess anthropometric change.
Body composition change
Body fat mass (BFM), body fat percentage (%BF) and body mass density (BMD) will be evaluated to assess body composition change. BFM and %BF will be assessed using multifrequency bioelectrical impedance analysis (BIA) and dual energy X-ray absorptiometry (DXA) and BMD will be assessed using DXA.

Secondary Outcome Measures

Change in inflammation parameters
TNF-alfa
Change in inflammation parameters
Interleucin 6 (IL6), IL1, IL10
Change in inflammation parameters
Adiponectin
Change in inflammation parameters
C-reactive protein (CRP)
Change in inflammation parameters
Neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR)
Change in metabolic parameters
Lipid profile (total cholesterol, LDL-c, HDL-c, VLDL-c), insulin resistance (HOMA-IR, glycated hemoglobin), fasting glycaemia, hemogram
Change in kidney function
Creatinine, urea and uric acid
Change in liver function
AST and ALT
Change in thyroid function
TSH, T4 and parathyroid hormone
Change in vitamins
Vitamin D, vitamin B12 and folic acid
Change in minerals
Iron, calcium, sodium, potassium and zinc
Change in cardiovascular risk using Global Risk Score (GRS)
Change in cardiovascular risk using Framingham Risk Score (FRS)
Change in cardiovascular risk using heart rate variability (HRV)
Change in cardiovascular risk using Homocystein level
Polymorphism Pro12Ala of Peroxisome Proliferator-Activated Receptor Alfa (PPAR-alfa)
Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism
PolymorphismTrp64Arg of Beta-3 Adrenergic Receptor (ADRB3) gene
Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism
Polymorphism -174G>C of Interleukin 6 (IL6) gene.
Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism
Change in physical activity practice using Global Physical Activity Questionnaire
Change in physical activity practice using accelerometry
Change in food intake using Food Frequency Questionnaire
Change in food intake using 24 hour recall
Change in bone health parameters
Change in the following variables: bone density using DXA, falls and fractures and sun exposure
Change in obesity sarcopenia using muscle mass (evaluated using DXA)
Change in obesity sarcopenia using handgrip strength
Change in sarcopenia using usual gait speed
Adherence to nutritional intervention
It will be evaluated through changes in food consumption (food frequency questionnaire)
Adherence to the health service
It will be evaluated through attendance to the clinic visits
Change in symptoms of anxiety and depression using Hospital Anxiety and Depression Scale
Change in symptoms of binge eating disorderusing Binge Eating Disorder Scale
Change in musculoskeletal pain using Visual Analog Scale
Change in musculoskeletal pain using Nordic Musculoskeletal Questionnaire

Full Information

First Posted
May 29, 2015
Last Updated
November 10, 2020
Sponsor
Universidade Federal de Goias
Collaborators
Fundação de Amparo a Pesquisa do Estado de Goias (FAPEG), Unidade de Pesquisa Clinica (UPC) do Hospital das Clínicas/UFG, Grupo de Estudos em Obesidade Grave (GEOG)
search

1. Study Identification

Unique Protocol Identification Number
NCT02463435
Brief Title
Effect of Nutritional Intervention and Olive Oil in Severe Obesity
Official Title
Effect of Nutritional Intervention and Olive Oil in Severe Obesity: Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
June 2015 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidade Federal de Goias
Collaborators
Fundação de Amparo a Pesquisa do Estado de Goias (FAPEG), Unidade de Pesquisa Clinica (UPC) do Hospital das Clínicas/UFG, Grupo de Estudos em Obesidade Grave (GEOG)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Obesity is a worldwide epidemic with increasing prevalence, specially severe obesity (Body Mass Index (BMI) ≥ 35 kg/m2). It is a multifactorial disease that involves genetic and environmental factors that lead to increased mortality from cardiovascular disease, diabetes, cancer, among others and impairs life quality. Most research on severe obesity focuses on surgical alternatives and their results, thus this clinical trial aims to evaluate the effect of a non-pharmacological approach based on nutritional intervention and supplementation with a functional food, the olive oil. It will analyze the effectiveness of interventions on: weight loss, improvements on body composition and inflammatory profile (TNF-alfa, interleucins 1, 6 and 10, adiponectin), insulin resistance and serum lipids control, changing eating habits and physical activity practice, modification on bone mineral density and sarcopenia, and reduction of cardiovascular risk and other diseases. Also, it will be investigated the influence of polymorphisms (Pro12Ala of PPAR-γ gene, -174G>C of IL6 gene e Trp64Arg of ADRB3 gene) on nutritional intervention effectiveness with and without olive oil. This research looks for improving severely obese patient's care and contributing to effective results by reducing costs and risk treatment. The investigators believe that this informations will contribute significantly to the scientific field, expanding the knowledge about severe obesity.
Detailed Description
After enrollment, patients undergo a diagnostic phase (baseline) with nutritional, anthropometric and body composition assessment (multifrequency bioelectrical impedance analysis and dual X-ray absorptiometry); investigation of clinical history; collecting blood samples; carotid artery intima-media thickness, heart rate variability and accelerometry assessments; and application of validated questionnaires to evaluate secondary outcomes. Patients will be randomized into three different treatment groups. Randomization will be stratified according to Body Mass Index (BMI) (BMI between 35 and 39,99 kg/m2 and BMI ≥ 40 kg/m2), allocation ratio 1:1:1 and parallel intervention. Then, trained nutritionists will deliver the intervention according to the patient group and they will be followed-up for 12 weeks, with visits each 4 weeks. Interventions will be provided as follow: Olive oil group: in order to evaluate the effect of only the extra virgin olive oil on primary and secondary outcomes, patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily (4 sachets per day, 2 at lunch and 2 at dinner). Nutritional intervention group: patients assigned to this group will receive nutritional intervention consisting of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Resting Energy Expenditure (REE) will be calculated according to Horie-Waitzberg & Gonzalez equation developed for severe obese individual using current weight and lean body mass (Horie et al., 2011). Total energy expenditure (TEE) will be calculated multiplying REE by activity factor recommended by Institute of Medicine (Trumbo et al., 2005) and thermic effect of food (Hill, Wyat, Peters, 2012). Total energy value (TEV) of diet will be determined reducing 550 to 1100 kcal from TEE to reach 0.5 to 1.0 weekly weight reduction according to the patient's individual goal. Distribution of macronutrients will follow Dietary Reference Intake (DRI) recommendation: 45-65% of carbohydrates, 10-35% of proteins and 20-35% of lipids (Trumbo et al., 2002). Fat acids (FA) will be distributed as recommended by Sociedade Brasileira de Cardiologia (Sposito et al., 2007): ≤ 7% saturated FA, ≤ 20% monounsaturated FA and ≤ 7% polyunsaturated FA. Food plan prescription will distribute TEV in 4-6 meals. Motivation will be held to changing eating and lifestyle habits. Nutritional intervention plus olive oil: this group will receive conventional intervention plus supplementation of 52 mL of extra virgin olive oil daily (4 sachets per day, 2 at lunch and 2 at dinner). At the end of follow-up the same assessments performed at diagnostic phase will be held. To detect a reduction of 10 kg, with standard deviation of 30, which is in agreement with the study of Rodrigues e Silveira (2011), with a two-sided 5% significance level and a power of 80%, a sample size of 50 patients per group will be necessary, given an anticipated dropout rate of 42,9%. This research will be conducted at a capital of center Brazil, at Unidade de Pesquisa Clínica of Hospital das Clínica/UFG, Faculty of Medicine/UFG.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Obesity
Keywords
nutritional management, olive oil, weight loss, body composition, nutrigenomics, polymorphisms, cardiovascular risk, sarcopenia, inflammation, food intake, sedentary lifestyle, patient adherence, bone density

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
229 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nutritional intervention
Arm Type
Active Comparator
Arm Description
Patients under only nutritional intervention for weight loss
Arm Title
Nutritional intervention plus olive oil
Arm Type
Experimental
Arm Description
Patients under conventional treatment (nutritional intervention) plus extra virgin olive oil supplementation
Arm Title
Olive oil
Arm Type
Experimental
Arm Description
Patient under habitual food consumption plus extra virgin olive oil supplementation
Intervention Type
Behavioral
Intervention Name(s)
Nutritional intervention
Intervention Description
Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
Intervention Type
Other
Intervention Name(s)
Nutritional intervention plus olive oil
Intervention Description
Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
Intervention Type
Dietary Supplement
Intervention Name(s)
Olive oil
Intervention Description
Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
Primary Outcome Measure Information:
Title
Anthropometric measurements change
Description
Measurements of weight, arm circumference and Body Mass Index (BMI) will be evaluated to assess anthropometric change.
Time Frame
Baseline, week 12
Title
Body composition change
Description
Body fat mass (BFM), body fat percentage (%BF) and body mass density (BMD) will be evaluated to assess body composition change. BFM and %BF will be assessed using multifrequency bioelectrical impedance analysis (BIA) and dual energy X-ray absorptiometry (DXA) and BMD will be assessed using DXA.
Time Frame
Baseline, week 12
Secondary Outcome Measure Information:
Title
Change in inflammation parameters
Description
TNF-alfa
Time Frame
Baseline, week 12
Title
Change in inflammation parameters
Description
Interleucin 6 (IL6), IL1, IL10
Time Frame
Baseline, week 12
Title
Change in inflammation parameters
Description
Adiponectin
Time Frame
Baseline, week 12
Title
Change in inflammation parameters
Description
C-reactive protein (CRP)
Time Frame
Baseline, week 12
Title
Change in inflammation parameters
Description
Neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ratio (LMR)
Time Frame
Baseline, week 12
Title
Change in metabolic parameters
Description
Lipid profile (total cholesterol, LDL-c, HDL-c, VLDL-c), insulin resistance (HOMA-IR, glycated hemoglobin), fasting glycaemia, hemogram
Time Frame
Baseline, week 12
Title
Change in kidney function
Description
Creatinine, urea and uric acid
Time Frame
Baseline, week 12
Title
Change in liver function
Description
AST and ALT
Time Frame
Baseline, week 12
Title
Change in thyroid function
Description
TSH, T4 and parathyroid hormone
Time Frame
Baseline, week 12
Title
Change in vitamins
Description
Vitamin D, vitamin B12 and folic acid
Time Frame
Baseline, week 12
Title
Change in minerals
Description
Iron, calcium, sodium, potassium and zinc
Time Frame
Baseline, week 12
Title
Change in cardiovascular risk using Global Risk Score (GRS)
Time Frame
Baseline, week 12
Title
Change in cardiovascular risk using Framingham Risk Score (FRS)
Time Frame
Baseline, week 12
Title
Change in cardiovascular risk using heart rate variability (HRV)
Time Frame
Baseline, week 12
Title
Change in cardiovascular risk using Homocystein level
Time Frame
Baseline, week 12
Title
Polymorphism Pro12Ala of Peroxisome Proliferator-Activated Receptor Alfa (PPAR-alfa)
Description
Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism
Time Frame
Baseline, week12
Title
PolymorphismTrp64Arg of Beta-3 Adrenergic Receptor (ADRB3) gene
Description
Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism
Time Frame
Baseline, week12
Title
Polymorphism -174G>C of Interleukin 6 (IL6) gene.
Description
Difference in responses between intervention groups for anthropometric measurements (weight, arm circumference and body mass index) and body composition variables (body fat mass and body fat percentage) according to this polymorphism
Time Frame
Baseline, week12
Title
Change in physical activity practice using Global Physical Activity Questionnaire
Time Frame
Baseline, week 12
Title
Change in physical activity practice using accelerometry
Time Frame
Baseline, week 12
Title
Change in food intake using Food Frequency Questionnaire
Time Frame
Baseline, week 12
Title
Change in food intake using 24 hour recall
Time Frame
Baseline, week 12
Title
Change in bone health parameters
Description
Change in the following variables: bone density using DXA, falls and fractures and sun exposure
Time Frame
Baseline, week 12
Title
Change in obesity sarcopenia using muscle mass (evaluated using DXA)
Time Frame
Baseline, week 12
Title
Change in obesity sarcopenia using handgrip strength
Time Frame
Baseline, week 12
Title
Change in sarcopenia using usual gait speed
Time Frame
Baseline, week 12
Title
Adherence to nutritional intervention
Description
It will be evaluated through changes in food consumption (food frequency questionnaire)
Time Frame
Baseline, week 12
Title
Adherence to the health service
Description
It will be evaluated through attendance to the clinic visits
Time Frame
Baseline, week 12
Title
Change in symptoms of anxiety and depression using Hospital Anxiety and Depression Scale
Time Frame
Baseline, week 12
Title
Change in symptoms of binge eating disorderusing Binge Eating Disorder Scale
Time Frame
Baseline, week 12
Title
Change in musculoskeletal pain using Visual Analog Scale
Time Frame
Baseline, week 12
Title
Change in musculoskeletal pain using Nordic Musculoskeletal Questionnaire
Time Frame
Baseline, week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Body mass index ≥ 35 kg/m2 Residence in Goiânia or metropolitan area Patients referred by Secretaria Municipal de Saúde to Severe Obese Nutrition Clinic Exclusion Criteria: To have already performed bariatric surgery Pregnancy Reduction greater than 8% of body weight in the past 3 months To have been treated at Severe Obesity Nutrition Clinic or have received nutritional counseling in another place in the last 2 years Anti-obesity drugs use Regular utilization of anti-inflammatory drugs or corticosteroids HIV/AIDS, heart failure, kidney failure, hepatic insufficiency, chronic obstructive pulmonary disease and cancer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Erika A Silveira, PhD
Organizational Affiliation
Universidade Federal de Goias - Faculdade de Medicina
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ana Paula S Rodrigues, MsC
Organizational Affiliation
Universidade Federal de Goias - Faculdade de Medicina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jacqueline D Souza, MsC
Organizational Affiliation
Universidade Federal de Goias - Faculdade de Medicina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Camila KS Cardoso, MsC
Organizational Affiliation
Universidade Federal de Goias - Faculdade de Medicina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lorena PS Rosa, MsC
Organizational Affiliation
Universidade Federal de Goias - Faculdade de Medicina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Annelisa SA Santos, MsC
Organizational Affiliation
Universidade Federal de Goias - Faculdade de Medicina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andrea BS Canheta, MsC
Organizational Affiliation
Universidade Federal de Goias - Faculdade de Medicina
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Carolina R Mendonça, MsC
Organizational Affiliation
Universidade Federal de Goias - Faculdade de Medicina
Official's Role
Principal Investigator
Facility Information:
Facility Name
Unidade de Pesquisa Clínica do Hospital das Clínicas/UFG
City
Goiânia
State/Province
Goiás
ZIP/Postal Code
74605-020
Country
Brazil

12. IPD Sharing Statement

Citations:
PubMed Identifier
22753534
Citation
Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. Circulation. 2012 Jul 3;126(1):126-32. doi: 10.1161/CIRCULATIONAHA.111.087213.
Results Reference
background
PubMed Identifier
21233808
Citation
Horie LM, Gonzalez MC, Torrinhas RS, Cecconello I, Waitzberg DL. New specific equation to estimate resting energy expenditure in severely obese patients. Obesity (Silver Spring). 2011 May;19(5):1090-4. doi: 10.1038/oby.2010.326. Epub 2011 Jan 13.
Results Reference
background
PubMed Identifier
17515982
Citation
Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune Neto A, Souza AD, Lottenberg AM, Chacra AP, Faludi AA, Loures-Vale AA, Carvalho AC, Duncan B, Gelonese B, Polanczyk C, Rodrigues Sobrinho CR, Scherr C, Karla C, Armaganijan D, Moriguchi E, Saraiva F, Pichetti G, Xavier HT, Chaves H, Borges JL, Diament J, Guimaraes JI, Nicolau JC, dos Santos JE, de Lima JJ, Vieira JL, Novazzi JP, Faria Neto JR, Torres KP, Pinto Lde A, Bricarello L, Bodanese LC, Introcaso L, Malachias MV, Izar MC, Magalhaes ME, Schmidt MI, Scartezini M, Nobre M, Foppa M, Forti NA, Berwanger O, Gebara OC, Coelho OR, Maranhao RC, dos Santos Filho RD, Costa RP, Barreto S, Kaiser S, Ihara S, Carvalho Td, Martinez TL, Relvas WG, Salgado W; Sociedade Brasileira de Cardiologia. [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology]. Arq Bras Cardiol. 2007 Apr;88 Suppl 1:2-19. doi: 10.1590/s0066-782x2007000700002. No abstract available. Portuguese.
Results Reference
background
PubMed Identifier
12449285
Citation
Trumbo P, Schlicker S, Yates AA, Poos M; Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002 Nov;102(11):1621-30. doi: 10.1016/s0002-8223(02)90346-9. No abstract available. Erratum In: J Am Diet Assoc. 2003 May;103(5):563.
Results Reference
background
PubMed Identifier
35586621
Citation
Silveira EA, Rosa LPS, de Resende DP, Rodrigues APDS, da Costa AC, Rezende ATO, Noll M, de Oliveira C, Junqueira-Kipnis AP. Positive Effects of Extra-Virgin Olive Oil Supplementation and DietBra on Inflammation and Glycemic Profiles in Adults With Type 2 Diabetes and Class II/III Obesity: A Randomized Clinical Trial. Front Endocrinol (Lausanne). 2022 May 2;13:841971. doi: 10.3389/fendo.2022.841971. eCollection 2022.
Results Reference
derived
PubMed Identifier
34836393
Citation
Longhi R, Santos ASEAC, Lopez-Yerena A, Rodrigues APS, Oliveira C, Silveira EA. The Effectiveness of Extra Virgin Olive Oil and the Traditional Brazilian Diet in Reducing the Inflammatory Profile of Individuals with Severe Obesity: A Randomized Clinical Trial. Nutrients. 2021 Nov 19;13(11):4139. doi: 10.3390/nu13114139.
Results Reference
derived
PubMed Identifier
32992832
Citation
Kellen de Souza Cardoso C, Gondim Peixoto MDR, Dos Santos Rodrigues AP, Rodrigues Mendonca C, de Oliveira C, Aparecida Silveira E. Bone Mineral Density in Severely Obese Women: Health Risk and Health Protective Risk Factors in Three Different Bone Sites. Int J Environ Res Public Health. 2020 Sep 25;17(19):7017. doi: 10.3390/ijerph17197017.
Results Reference
derived
PubMed Identifier
32675019
Citation
Canheta ABS, Santos ASEAC, Souza JD, Silveira EA. Traditional Brazilian diet and extra virgin olive oil reduce symptoms of anxiety and depression in individuals with severe obesity: Randomized clinical trial. Clin Nutr. 2021 Feb;40(2):404-411. doi: 10.1016/j.clnu.2020.05.046. Epub 2020 Jun 10.
Results Reference
derived
PubMed Identifier
32455620
Citation
Aparecida Silveira E, Danesio de Souza J, Dos Santos Rodrigues AP, Lima RM, de Souza Cardoso CK, de Oliveira C. Effects of Extra Virgin Olive Oil (EVOO) and the Traditional Brazilian Diet on Sarcopenia in Severe Obesity: A Randomized Clinical Trial. Nutrients. 2020 May 21;12(5):1498. doi: 10.3390/nu12051498.
Results Reference
derived
PubMed Identifier
32032997
Citation
Cardoso CKS, Santos ASEAC, Rosa LPS, Mendonca CR, Vitorino PVO, Peixoto MDRG, Silveira EA. Effect of Extra Virgin Olive Oil and Traditional Brazilian Diet on the Bone Health Parameters of Severely Obese Adults: A Randomized Controlled Trial. Nutrients. 2020 Feb 4;12(2):403. doi: 10.3390/nu12020403.
Results Reference
derived
PubMed Identifier
30026785
Citation
Rodrigues APS, Rosa LPS, Silveira EA. PPARG2 Pro12Ala polymorphism influences body composition changes in severely obese patients consuming extra virgin olive oil: a randomized clinical trial. Nutr Metab (Lond). 2018 Jul 17;15:52. doi: 10.1186/s12986-018-0289-4. eCollection 2018.
Results Reference
derived

Learn more about this trial

Effect of Nutritional Intervention and Olive Oil in Severe Obesity

We'll reach out to this number within 24 hrs